化合物Bozitinib T10585
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
TargetMol | 生产商 | 美国 | 现货 |
性能特点
生化试剂,可用于动物细胞实验
规格 | CAS号 | 价格 | 操作 |
---|---|---|---|
5 mg | 1440964-89-5 | ¥2,890.00 | 询底价 |
1 mL | 1440964-89-5 | ¥3,180.00 | 询底价 |
50 mg | 1440964-89-5 | ¥9,270.00 | 询底价 |
1 mg | 1440964-89-5 | ¥996.00 | 询底价 |
25 mg | 1440964-89-5 | ¥6,830.00 | 询底价 |
100 mg | 1440964-89-5 | ¥12,300.00 | 询底价 |
10 mg | 1440964-89-5 | ¥4,280.00 | 询底价 |
Product Introduction
Bioactivity
英文名: Bozitinib
描述: Bozitinib (PLB-1001) 是一种可透过血脑屏障的、高效的、选择性的的、 ATP 竞争性的小分子 c-MET 激酶抑制剂,能够与酪氨酸激酶超家族的常规 ATP 结合口袋结合。
体外活性: Bozitinib (30 μM; 6 hours) inhibits the phosphorylation of MET and STAT3. Bozitinib has a robust inhibitory effect on MET and its downstream signaling pathways.
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: DMSO : 47 mg/mL (110.74 mM)
关键字: PLB1001 | Vebreltinib | CBT 101 | inhibit | c-Met/HGFR | Bozitinib | CBT101 | PLB 1001 | Inhibitor
相关产品: Crizotinib hydrochloride | SGX-523 | Glumetinib | Onartuzumab | Tyrosine kinase-IN-6 | SU11274 | BMS-794833 | Golvatinib | Norcantharidin | Cabozantinib hydrochloride
相关库: Drug Repurposing Compound Library | FDA-Approved Kinase Inhibitor Library | Anti-Cancer Drug Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Inhibitor Library | Anti-Cancer Active Compound Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Approved Drug Library | Highly Selective Inhibitor Library
化合物Bozitinib T10585信息由TargetMol中国为您提供,如您想了解更多关于化合物Bozitinib T10585报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途